One of the hottest topics in drug discovery circles right now is how the big Pfizer/Wyeth merger will play out in the companies' labs. Analysts have already been buzzing about the likelihood of billions of dollars in cuts as the two R&D operations are melded into one big outfit. But Martin Mackay and Mikael Dolsten, who will head up the company's two wings of research, are publicly concentrating more on the structure of their new drug discovery domain rather than the number of scientists likely to get laid off. Report